BLFS

SEC source: 0001628280-25-034682 · wk-form4_1752098045.xml · nonDerivative · entry 1

Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 352,582

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001628280-25-034681 · wk-form4_1752098033.xml · nonDerivative · entry 1

Berard Todd · CIK 0001633186 · Chief Marketing Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 134,618

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001628280-25-032190 · wk-form4_1750283050.xml · nonDerivative · entry 1

Aebersold Sarah · CIK 0001837756 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 78,721

F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 12-11-2024.

SEC source: 0000919574-25-003572 · ownership.xml · nonDerivative · entry 1

Casdin Partners Master Fund, L.P. · CIK 0001534265 · 10% owner

Casdin Capital, LLC · CIK 0001534261 · 10% owner

Casdin Partners GP, LLC · CIK 0001534260 · 10% owner

Casdin Eli · CIK 0001534264 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 7,707,165

F1 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin Capital"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC ("Casdin GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP.

SEC source: 0001628280-25-031103 · wk-form4_1749763471.xml · nonDerivative · entry 1

Berard Todd · CIK 0001633186 · Chief Marketing Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 134,922

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-08-2024 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001628280-25-031102 · wk-form4_1749763462.xml · nonDerivative · entry 1

Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 353,118

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-08-2024 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001628280-25-031101 · wk-form4_1749763452.xml · nonDerivative · entry 1

Wichterman Troy · CIK 0001892616 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 186,685

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-08-2024 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001628280-25-031099 · wk-form4_1749763432.xml · nonDerivative · entry 1

Aebersold Sarah · CIK 0001837756 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 79,432

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-08-2024 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001628280-25-031100 · wk-form4_1749763442.xml · nonDerivative · entry 1

Werner Sean · CIK 0002047541 · Chief Technology Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,610

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 09-01-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001628280-25-031097 · wk-form4_1749763422.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 194,996

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-08-2024 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001628280-25-028700 · wk-form4_1748642526.xml · nonDerivative · entry 2

Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 353,755

F2 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan (the "2023 Plan") and fully vests on the fourth anniversary of the measurement date of 05-29-2025.

SEC source: 0001628280-25-028708 · wk-form4_1748642829.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 195,316

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001628280-25-028707 · wk-form4_1748642842.xml · nonDerivative · entry 1

Aebersold Sarah · CIK 0001837756 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 79,667

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001628280-25-028704 · wk-form4_1748642758.xml · nonDerivative · entry 1

Berard Todd · CIK 0001633186 · Chief Marketing Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 135,284

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001628280-25-028700 · wk-form4_1748642526.xml · nonDerivative · entry 1

Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 308,486

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001628280-25-028695 · wk-form4_1748642210.xml · nonDerivative · entry 1

Werner Sean · CIK 0002047541 · Chief Technology Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,675

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001628280-25-028692 · wk-form4_1748642060.xml · nonDerivative · entry 1

Wichterman Troy · CIK 0001892616 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 187,727

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001628280-25-017588 · wk-form4_1744408167.xml · nonDerivative · entry 1

Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 309,007

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001628280-25-017589 · wk-form4_1744408177.xml · nonDerivative · entry 1

Wichterman Troy · CIK 0001892616 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 188,310

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001628280-25-017587 · wk-form4_1744408157.xml · nonDerivative · entry 1

Aebersold Sarah · CIK 0001837756 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 79,884

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001628280-25-017586 · wk-form4_1744408146.xml · nonDerivative · entry 1

Berard Todd · CIK 0001633186 · Chief Marketing Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 135,632

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001628280-25-017585 · wk-form4_1744408136.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 195,567

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0000919574-25-002362 · ownership.xml · nonDerivative · entry 1

Casdin Partners Master Fund, L.P. · CIK 0001534265 · 10% owner

Casdin Capital, LLC · CIK 0001534261 · 10% owner

Casdin Partners GP, LLC · CIK 0001534260 · 10% owner

Casdin Eli · CIK 0001534264 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 8,735,159

F1 · kind: Received in exchange for shares of common stock of PanThera CryoSolutions, Inc. ("PanThera") pursuant to the acquisition of PanThera by Biolife Solutions Inc (the "Company"). Per the terms of the acquisition, the Company purchased 90% of PanTHERA common shares it did not own for $9.3 million in cash and 241,355 shares of the Company's Common Stock, par value $.001 per share. The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP.

F1 · price: Received in exchange for shares of common stock of PanThera CryoSolutions, Inc. ("PanThera") pursuant to the acquisition of PanThera by Biolife Solutions Inc (the "Company"). Per the terms of the acquisition, the Company purchased 90% of PanTHERA common shares it did not own for $9.3 million in cash and 241,355 shares of the Company's Common Stock, par value $.001 per share. The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP.

F1 · ownership.nature: Received in exchange for shares of common stock of PanThera CryoSolutions, Inc. ("PanThera") pursuant to the acquisition of PanThera by Biolife Solutions Inc (the "Company"). Per the terms of the acquisition, the Company purchased 90% of PanTHERA common shares it did not own for $9.3 million in cash and 241,355 shares of the Company's Common Stock, par value $.001 per share. The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP.

SEC source: 0001628280-25-016635 · wk-form4_1743716896.xml · nonDerivative · entry 1

Wichterman Troy · CIK 0001892616 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 189,242

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001628280-25-016637 · wk-form4_1743716917.xml · nonDerivative · entry 1

Aebersold Sarah · CIK 0001837756 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 80,094

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001628280-25-016636 · wk-form4_1743716906.xml · nonDerivative · entry 1

Berard Todd · CIK 0001633186 · Chief Marketing Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 135,956

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001628280-25-016634 · wk-form4_1743716886.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 195,853

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001628280-25-016633 · wk-form4_1743716875.xml · nonDerivative · entry 1

Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 309,576

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001628280-25-014194 · wk-form4_1742512247.xml · nonDerivative · entry 2

Aebersold Sarah · CIK 0001837756 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,865

F2 · price: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 175% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

SEC source: 0001628280-25-014194 · wk-form4_1742512247.xml · nonDerivative · entry 1

Aebersold Sarah · CIK 0001837756 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,076

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2025 compensation.

SEC source: 0001628280-25-014192 · wk-form4_1742512170.xml · nonDerivative · entry 2

DuRoss Amy · CIK 0001854968 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,687

F3 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan (the "2023 Plan") and fully vests on the first anniversary of the measurement date of 01-02-2025.

SEC source: 0001628280-25-014191 · wk-form4_1742512161.xml · nonDerivative · entry 1

Coste Catherine · CIK 0001821432 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,701

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan (the "2023 Plan") and fully vests on the first anniversary of the measurement date of 01-02-2025.

SEC source: 0001628280-25-014190 · wk-form4_1742512151.xml · nonDerivative · entry 1

Hunt Anthony · CIK 0001606030 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,876

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan (the "2023 Plan") and fully vests on the first anniversary of the measurement date of 01-02-2025.

SEC source: 0001628280-25-014189 · wk-form4_1742512140.xml · nonDerivative · entry 1

MOORE TIMOTHY L. · CIK 0001669207 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,773

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan (the "2023 Plan") and fully vests on the first anniversary of the measurement date of 01-02-2025.

SEC source: 0001628280-25-014187 · wk-form4_1742512119.xml · nonDerivative · entry 2

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 203,722

F2 · price: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 175% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

SEC source: 0001628280-25-014187 · wk-form4_1742512119.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 174,011

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2025 compensation.

SEC source: 0001628280-25-014186 · wk-form4_1742512108.xml · nonDerivative · entry 1

Ellingson Rachel · CIK 0001557271 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,825

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan (the "2023 Plan") and fully vests on the first anniversary of the measurement date of 01-02-2025.

SEC source: 0001628280-25-014184 · wk-form4_1742512090.xml · nonDerivative · entry 2

Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 320,165

F2 · price: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 175% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

SEC source: 0001628280-25-014184 · wk-form4_1742512090.xml · nonDerivative · entry 1

Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 283,520

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2025 compensation.

SEC source: 0001628280-25-014183 · wk-form4_1742512080.xml · nonDerivative · entry 2

Berard Todd · CIK 0001633186 · Chief Marketing Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 144,858

F2 · price: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 175% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

SEC source: 0001628280-25-014183 · wk-form4_1742512080.xml · nonDerivative · entry 1

Berard Todd · CIK 0001633186 · Chief Marketing Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 124,060

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2025 compensation.

SEC source: 0001628280-25-014182 · wk-form4_1742512070.xml · nonDerivative · entry 2

Wichterman Troy · CIK 0001892616 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 214,929

F2 · price: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 175% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

SEC source: 0001628280-25-014182 · wk-form4_1742512070.xml · nonDerivative · entry 1

Wichterman Troy · CIK 0001892616 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 154,911

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2025 compensation.

SEC source: 0001628280-25-014180 · wk-form4_1742512051.xml · nonDerivative · entry 1

Werner Sean · CIK 0002047541 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,784

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2025 compensation.

SEC source: 0001628280-25-014181 · wk-form4_1742512061.xml · nonDerivative · entry 1

GOSWAMI JOYDEEP · CIK 0001533115 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,986

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan (the "2023 Plan") and fully vests on the first anniversary of the measurement date of 01-02-2025.

SEC source: 0001628280-25-014179 · wk-form4_1742512041.xml · nonDerivative · entry 1

DE GREEF RODERICK · CIK 0001241181 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 527,793

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2025 compensation.

SEC source: 0001628280-25-013585 · wk-form4_1742335183.xml · nonDerivative · entry 2

Aebersold Sarah · CIK 0001837756 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 43,165

F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 12-11-2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.90 to $25.97, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001628280-25-014185 · wk-form4a_1742512099.xml · nonDerivative · entry 1

Aebersold Sarah · CIK 0001837756 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,797

F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 12-11-2024.

F2 · shares: This Form 4 amendment has been filed to correct the amount of securities reported in a Form 4 filed on March 18, 2025. The Form 4 included a sale of 5,632 shares that was improperly included under the reporting person. The correct amount of securities should have been reported as 2,695 in the Form 4.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.90 to $25.97, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001628280-25-013585 · wk-form4_1742335183.xml · nonDerivative · entry 1

Aebersold Sarah · CIK 0001837756 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,860

F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 12-11-2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.18 to $25.91, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001628280-25-014192 · wk-form4_1742512170.xml · nonDerivative · entry 1

DuRoss Amy · CIK 0001854968 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,811

F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 12-13-2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.18 to $25.91, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.